Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Pylera 140mg/125mg/125mg capsules
0103050A0BDAAAC
|
Pylera | Helicobacter pylori eradication therapy | Gastro-Intestinal System | 75 |
|
Rennie Spearmint chewable tablets
010102100BBARAF
|
Proprietary compound preparation BNF 0101021 | Compound alginates and proprietary indigestion preparations | Gastro-Intestinal System | 75 |
|
Urea [13-C] 45mg oral powder breath test kit sugar free
010300000AAAEAE
|
Generic compound preparation BNF 0103000 | Other test for helicobacter pylori preparations | Gastro-Intestinal System | 71 |
|
Glycopyrronium bromide 500micrograms/5ml oral solution
0102000L0AABHBH
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | 69 |
|
Generic Picolax oral powder 16.1g sachets sugar free
0106050S0AAAAAA
|
Sodium picosulfate (Bowel Cleansing) | Sodium picosulfate | Gastro-Intestinal System | 64 |
|
Ranitidine 75mg tablets
0103010T0AAAPAP
|
Ranitidine hydrochloride | Ranitidine hydrochloride | Gastro-Intestinal System | 64 |
|
Imodium IBS Relief 2mg capsules
0104020L0BBALAA
|
Imodium | Loperamide hydrochloride | Gastro-Intestinal System | 61 |
|
Entocort 2mg/100ml enema
0105020A0BBABAB
|
Entocort | Budesonide | Gastro-Intestinal System | 59 |
|
Laxido Orange oral powder sachets
0106040M0BCAAAE
|
Laxido | Macrogol 3350 | Gastro-Intestinal System | 59 |
|
Senna 7.5mg/5ml oral solution
0106020M0AAAEAE
|
Senna | Senna | Gastro-Intestinal System | 59 |
|
Co-danthrusate 50mg/60mg/5ml oral suspension sugar free
0106020J0AAADAD
|
Co-danthrusate | Co-danthrusate (Dantron/docusate sodium) | Gastro-Intestinal System | 56 |
|
Magdose 160mg capsules
0101010I0BFADAC
|
Magdose | Magnesium oxide | Gastro-Intestinal System | 56 |
|
Oily phenol 5% solution for injection 5ml ampoules
0107030P0AAADAD
|
Phenol in oil | Phenol | Gastro-Intestinal System | 54 |
|
Magnesium sulfate powder
0106040L0AAABAB
|
Mag sulf (Laxative) | Magnesium sulfate | Gastro-Intestinal System | 52 |
|
Sod dihydrogen phos anhydrous 340mg/Sod bicarb 250mg suppos
0106040N0AAAGAG
|
Phosphate (Rectal) | Phosphates (Rectal) | Gastro-Intestinal System | 52 |
|
Cytotec 200microgram tablets
0103040M0BBAAAA
|
Cytotec | Misoprostol | Gastro-Intestinal System | 50 |
|
Omeprazole 40mg/5ml oral solution
0103050P0AAAKAK
|
Omeprazole | Omeprazole | Gastro-Intestinal System | 50 |
|
Helicobacter Test INFAI for children breath test kit
010300000BBAEAE
|
Proprietary compound preparation BNF 0103000 | Other test for helicobacter pylori preparations | Gastro-Intestinal System | 48 |
|
Ranitidine 150mg/5ml oral solution sugar free
0103010T0AABUBU
|
Ranitidine hydrochloride | Ranitidine hydrochloride | Gastro-Intestinal System | 48 |
|
Sucralfate 2g/50ml enema
0107010S0AAALAL
|
Sucralfate (Rectal) | Sucralfate | Gastro-Intestinal System | 48 |
|
Glycopyrronium bromide 2mg/5ml oral liquid
0102000L0AAAIAI
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | 46 |
|
Magnesium oxide 400mg tablets
0101010I0AABIBI
|
Magnesium oxide | Magnesium oxide | Gastro-Intestinal System | 46 |
|
Glycopyrronium bromide 500micrograms/5ml oral suspension
0102000L0AABIBI
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | 45 |
|
Citric acid 17.79g/Magnesium carb 11.57g efferv pdr sach SF
0106050M0AAAAAA
|
Magnesium citrate (Bowel Cleansing) | Magnesium citrate | Gastro-Intestinal System | 44 |
|
Glycopyrronium bromide 2.5mg/5ml oral suspension
0102000L0AABCBC
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | 44 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.